Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. - Wikidata - awgldk - TriplyDB

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

http://www.wikidata.org/entity/Q34040130

about

The imaging viewpoint: how imaging affects determination of progression-free survival Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Overview: progression-free survival as an endpoint in clinical trials with solid tumors.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.Bias, Operational Bias, and Generalizability in Phase II/III Trials.Surrogate endpoints in advanced sarcoma trials: a meta-analysis

P2860

Q34719348-D38837A2-2F45-451E-9D77-AFB98CBAC7A9 Q36433053-B944F1B4-8032-4C44-AF5F-9849A0B49609 Q37053820-1DA2D4D9-F9F0-4001-B6C7-F7477FDB990A Q38106563-BC163C0B-DA40-488F-AF14-08BA3885BB2B Q40824695-0A4EBBC3-19DF-45B9-A3A4-1A41CB9EE1AE Q42763247-B60C9E96-7639-453C-BE84-B49992AA1FBA Q53281780-9E7A3690-C611-4521-BAA5-7B5C2E467E15 Q57818331-2670C736-E112-4FE9-8351-52A833E5AA4B

P2860

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

http://www.wikidata.org/entity/Q34040130

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Modeling the relationship betw ...... vival: the phase II/III trial.

@ast

Modeling the relationship betw ...... vival: the phase II/III trial.

@en

Modeling the relationship betw ...... vival: the phase II/III trial.

@nl

type

label

Modeling the relationship betw ...... vival: the phase II/III trial.

@ast

Modeling the relationship betw ...... vival: the phase II/III trial.

@en

Modeling the relationship betw ...... vival: the phase II/III trial.

@nl

prefLabel

Modeling the relationship betw ...... vival: the phase II/III trial.

@ast

Modeling the relationship betw ...... vival: the phase II/III trial.

@en

Modeling the relationship betw ...... vival: the phase II/III trial.

@nl

P1433

Q34040130-E311AE37-CD0C-4ED5-A019-0633289BCC1C

P1476

Q34040130-20017511-8A8C-4DE8-99BE-F2B605DB1EF4

P2093

Q34040130-18300012-06E9-4A28-B195-42B980998002

Q34040130-315CC68C-FF36-487E-9219-F22EFEF53C8E

Q34040130-3790E1A8-99BB-4DD0-9162-F0461B2CE888

Q34040130-72532949-139F-4B6A-A5C7-E56BD6D2ABF3

Q34040130-B13AD880-39DB-4F97-8C9B-B1ABEBDA53A4

P2860

Q34040130-01B3743E-0C0D-4721-80E4-A278CB1EAD73

Q34040130-047BA9B6-1363-4E83-8FA8-B4AFCE559556

Q34040130-08BAA8B1-10D4-426C-8694-10EF72761CA4

Q34040130-0EFAD5CF-5516-4665-8ADA-05B4D14730D4

Q34040130-13F9CD34-B4F3-4CE6-BEB8-38CA7CF6B07E

Q34040130-1487F5DA-8C5F-416C-AFEA-34D21BC1ED3B

Q34040130-148A0E5C-205D-4166-8344-87AF7BC40826

Q34040130-19691002-8202-40E5-A6E5-7B078F0E3F7E

Q34040130-2310D3EB-9973-4B3D-947F-A3A1DAD1AB33

Q34040130-24E70BCC-F887-47BA-8734-96D60A1F02EB

P304

Q34040130-6D0A295B-CBE0-4F47-82D2-46AB6C789A19

P31

Q34040130-7FA195FB-A033-43C0-9772-ADCF10971838

P356

Q34040130-6AD4D0C5-62CA-4D7A-986B-C785372B656E

P407

Q34040130-12985ED4-2CB4-429D-8EAF-E28BB90420A0

P433

Q34040130-878745D0-4E0C-4A84-ABD3-DE8329525FC9

P478

Q34040130-DE324D75-54C6-4037-8E3E-F2CC6ADA6EB6

P577

Q34040130-1F0856AF-52A5-4097-8A3A-54B41D730006

P698

Q34040130-012B786C-CAB4-4C9D-B1F2-5C7D659CDF3E

P921

Q34040130-A25CD273-9E5C-447C-91E9-4299FA9F0A77

Q34040130-F14DB466-FC5F-43CE-8FEF-66160676192C

P932

Q34040130-CA5ABDDA-2475-45F5-8543-821A96002049

P356

1078-0432.CCR-12-2939

P1433

Clinical Cancer Research

P1476

Modeling the relationship betw ...... vival: the phase II/III trial.

@en

P2093

Anne Schott

http://www.w3.org/2001/XMLSchema#string

Bryan H Goldman

http://www.w3.org/2001/XMLSchema#string

Laurence H Baker

http://www.w3.org/2001/XMLSchema#string

Mary W Redman

http://www.w3.org/2001/XMLSchema#string

Michael LeBlanc

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

P304

2646-2656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2939

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23669424

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial

P932

4131693

http://www.w3.org/2001/XMLSchema#string